Tesamorelin
10mg
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH 1-44) with a trans-3-hexenoic acid modification at the N-terminus that confers enhanced stability against DPP-IV enzymatic degradation. It is the only FDA-approved GHRH analog (Egrifta), approved for reduction of excess visceral adipose tissue in HIV-associated lipodystrophy. Tesamorelin stimulates endogenous pulsatile GH secretion from anterior pituitary somatotrophs, preserving the natural feedback regulation that exogenous GH bypasses.
Select Option
10% OFF · ends July 31Mechanism of Action
Tesamorelin binds the GHRH receptor (GHRH-R) on pituitary somatotrophs, activating Gs-coupled cAMP/PKA signaling that stimulates GH gene transcription, GH synthesis, and GH secretory granule exocytosis. Unlike exogenous GH, tesamorelin preserves the pulsatile GH secretion pattern and maintains feedback sensitivity to somatostatin and IGF-1. This physiologic GH release preferentially reduces visceral adiposity through enhanced lipolysis while avoiding the supraphysiologic IGF-1 elevation associated with exogenous GH.
Properties
Molecular Formula
C₂₂₁H₃₆₆N₇₂O₆₇S₁
Molecular Weight
5135.89 Da
Half-Life
~26-38 minutes
Storage
Store lyophilized at 2-8°C. Reconstituted at 2-8°C, use within 14 days.
Research Applications
References & Citations
(2)Metabolic effects of a growth hormone-releasing factor in patients with HIV
Falutz J, Allas S, Blot K, et al.
Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation
Stanley TL, Feldpausch MN, Oh J, et al.
Research Use Only
This product is intended strictly for in-vitro research, educational, and laboratory use. Not for human consumption. The information provided is based on published research and does not constitute medical advice.